Price
$2.22
Decreased by -3.06%
Dollar Volume (20D)
12.69 K
ADR%
5.85
Earnings Report Date (estimate)
Apr 29, 24
Shares Float
5.48 B
Shares Outstanding
5.65 M
Shares Short
8.65 K
Market Cap.
13 M
Beta
1.05
Price / Earnings
N/A
20D Range
2.1 2.74
50D Range
2.1 3.31
200D Range
2.1 5.5
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Oct 12, 23 0
Increased by +100%
-0.6
Increased by +100%
Sep 29, 23 0
Increased by +100%
-1
Increased by +100%
May 1, 23 -0.08
Increased by +34.21%
-0.07
Decreased by -14.29%
Mar 30, 23 -0.08
Decreased by -156.41%
-0.07
Decreased by -14.29%
Dec 30, 22 -0.04
Increased by +73.65%
-0.04
Jul 20, 22 -0.1
Decreased by -866%
-
May 16, 22 -0.12
Decreased by -380.83%
-
Dec 3, 21 -0.03
Increased by +88.76%
-
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 N/A
Decreased by N/A%
N/A
Increased by +100%
- -
Mar 31, 23 N/A
Decreased by N/A%
N/A
Increased by +100%
- -
Dec 31, 22 N/A
Decreased by N/A%
N/A
Increased by +100%
- -
Sep 30, 22 N/A
Decreased by N/A%
N/A
Increased by +100%
- -
Jun 30, 22 0
Decreased by N/A%
-5.54 M
Decreased by -26.7%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by N/A%
-5.11 M
Increased by +12.5%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0
Decreased by N/A%
-5.61 M
Increased by +17.72%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0
Decreased by N/A%
-1.43 M
Decreased by -198.83%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.